Metabolic reprograming of cancer as a therapeutic target

Biochim Biophys Acta Gen Subj. 2023 Mar;1867(3):130301. doi: 10.1016/j.bbagen.2022.130301. Epub 2022 Dec 23.

Abstract

Our understanding of metabolic reprogramming in cancer has tremendously improved along with the technical progression of metabolomic analysis. Metabolic changes in cancer cells proved much more complicated than the classical Warburg effect. Previous studies have approached metabolic changes as therapeutic and/or chemopreventive targets. Recently, several clinical trials have reported anti-cancer agents associated with metabolism. However, whether cancer cells are dependent on metabolic reprogramming or favor suitable conditions remains nebulous. Both scenarios are possibly intertwined. Identification of downstream molecules and the understanding of mechanisms underlying reprogrammed metabolism can improve the effectiveness of cancer therapy. Here, we review several examples of the metabolic reprogramming of cancer cells and the therapies targeting the metabolism-related molecules as well as discuss practical approaches to improve the next generation of cancer therapies focused on the metabolic reprogramming of cancer.

Keywords: Anticancer agent; Clinical trial; Drug discovery; Metabolic reprograming; Therapeutic target.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Energy Metabolism
  • Glycolysis
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism

Substances

  • Antineoplastic Agents